70 related articles for article (PubMed ID: 12625783)
1. Application of proteomics in the search for novel proteins associated with the anti-cancer effect of the synthetic cyclin-dependent kinases inhibitor, bohemine.
Kovarova H; Halada P; Man P; Dzubak P; Hajduch M
Technol Cancer Res Treat; 2002 Aug; 1(4):247-56. PubMed ID: 12625783
[TBL] [Abstract][Full Text] [Related]
2. Proteomics approach in classifying the biochemical basis of the anticancer activity of the new olomoucine-derived synthetic cyclin-dependent kinase inhibitor, bohemine.
Kovárová H; Hajdúch M; Korínková G; Halada P; Krupicková S; Gouldsworthy A; Zhelev N; Strnad M
Electrophoresis; 2000 Nov; 21(17):3757-64. PubMed ID: 11271495
[TBL] [Abstract][Full Text] [Related]
3. Protein fingerprints of anti-cancer effects of cyclin-dependent kinase inhibition: identification of candidate biomarkers using 2-D liquid phase separation coupled to mass spectrometry.
Skalnikova H; Halada P; Dzubak P; Hajduch M; Kovarova H
Technol Cancer Res Treat; 2005 Aug; 4(4):447-54. PubMed ID: 16029063
[TBL] [Abstract][Full Text] [Related]
4. The radiosensitising effect of olomoucine derived synthetic cyclin-dependent kinase inhibitors.
Korinkova G; Cwiertka K; Paprskarova M; Dzubak P; Hajduch M
Neoplasma; 2010; 57(2):161-9. PubMed ID: 20099981
[TBL] [Abstract][Full Text] [Related]
5. Proteomic analysis of anti-cancer effects by paclitaxel treatment in cervical cancer cells.
Lee KH; Yim EK; Kim CJ; Namkoong SE; Um SJ; Park JS
Gynecol Oncol; 2005 Jul; 98(1):45-53. PubMed ID: 15907983
[TBL] [Abstract][Full Text] [Related]
6. Cancer drug-resistance and a look at specific proteins: Rho GDP-dissociation inhibitor 2, Y-box binding protein 1, and HSP70/90 organizing protein in proteomics clinical application.
Skalnikova H; Martinkova J; Hrabakova R; Halada P; Dziechciarkova M; Hajduch M; Gadher SJ; Hammar A; Enetoft D; Ekefjard A; Forsstrom-Olsson O; Kovarova H
J Proteome Res; 2011 Feb; 10(2):404-15. PubMed ID: 21067243
[TBL] [Abstract][Full Text] [Related]
7. Conformation and recognition of DNA damaged by antitumor cis-dichlorido platinum(II) complex of CDK inhibitor bohemine.
Novakova O; Liskova B; Vystrcilova J; Suchankova T; Vrana O; Starha P; Travnicek Z; Brabec V
Eur J Med Chem; 2014 May; 78():54-64. PubMed ID: 24675180
[TBL] [Abstract][Full Text] [Related]
8. Comparative proteomic analysis of paclitaxel sensitive A549 lung adenocarcinoma cell line and its resistant counterpart A549-Taxol.
Sun QL; Sha HF; Yang XH; Bao GL; Lu J; Xie YY
J Cancer Res Clin Oncol; 2011 Mar; 137(3):521-32. PubMed ID: 20499251
[TBL] [Abstract][Full Text] [Related]
9. Decrease in susceptibility toward induction of apoptosis and alteration in G1 checkpoint function as determinants of resistance of human lung cancer cells against the antisignaling drug UCN-01 (7-Hydroxystaurosporine).
Sugiyama K; Akiyama T; Shimizu M; Tamaoki T; Courage C; Gescher A; Akinaga S
Cancer Res; 1999 Sep; 59(17):4406-12. PubMed ID: 10485490
[TBL] [Abstract][Full Text] [Related]
10. Identification of human hepatocellular carcinoma-related biomarkers by two-dimensional difference gel electrophoresis and mass spectrometry.
Lee IN; Chen CH; Sheu JC; Lee HS; Huang GT; Yu CY; Lu FJ; Chow LP
J Proteome Res; 2005; 4(6):2062-9. PubMed ID: 16335951
[TBL] [Abstract][Full Text] [Related]
11. Cellular response to antitumor cis-Dichlorido platinum(II) complexes of CDK inhibitor Bohemine and its analogues.
Liskova B; Zerzankova L; Novakova O; Kostrhunova H; Travnicek Z; Brabec V
Chem Res Toxicol; 2012 Feb; 25(2):500-9. PubMed ID: 22250642
[TBL] [Abstract][Full Text] [Related]
12. In vitro and in vivo pharmacokinetic-pharmacodynamic relationships for the trisubstituted aminopurine cyclin-dependent kinase inhibitors olomoucine, bohemine and CYC202.
Raynaud FI; Whittaker SR; Fischer PM; McClue S; Walton MI; Barrie SE; Garrett MD; Rogers P; Clarke SJ; Kelland LR; Valenti M; Brunton L; Eccles S; Lane DP; Workman P
Clin Cancer Res; 2005 Jul; 11(13):4875-87. PubMed ID: 16000586
[TBL] [Abstract][Full Text] [Related]
13. Proteomic investigation of taxol and taxotere resistance and invasiveness in a squamous lung carcinoma cell line.
Murphy L; Henry M; Meleady P; Clynes M; Keenan J
Biochim Biophys Acta; 2008 Sep; 1784(9):1184-91. PubMed ID: 18503785
[TBL] [Abstract][Full Text] [Related]
14. Depletion of PKM2 leads to impaired glycolysis and cell death in 2-demethoxy-2,3-ethylenediamino hypocrellin B-photoinduced A549 cells.
Zhou Z; Liu Y; Qin M; Sheng W; Wang X; Li Z; Zhong R
J Photochem Photobiol B; 2014 May; 134():1-8. PubMed ID: 24792468
[TBL] [Abstract][Full Text] [Related]
15. A proteomic study on a human osteosarcoma cell line Saos-2 treated with diallyl trisulfide.
Zhang YK; Zhang XH; Li JM; Sun DS; Yang Q; Diao DM
Anticancer Drugs; 2009 Sep; 20(8):702-12. PubMed ID: 19550292
[TBL] [Abstract][Full Text] [Related]
16. Zinc(II) complexes with potent cyclin-dependent kinase inhibitors derived from 6-benzylaminopurine: synthesis, characterization, X-ray structures and biological activity.
Trávnícek Z; Krystof V; Sipl M
J Inorg Biochem; 2006 Feb; 100(2):214-25. PubMed ID: 16386795
[TBL] [Abstract][Full Text] [Related]
17. Differentially expressed proteins in human breast cancer cells sensitive and resistant to paclitaxel.
Pavlikova N; Bartonova I; Dincakova L; Halada P; Kovar J
Int J Oncol; 2014 Aug; 45(2):822-30. PubMed ID: 24898082
[TBL] [Abstract][Full Text] [Related]
18. Proteomic analysis of selective cytotoxic anticancer properties of flavonoids isolated from Citrus platymamma on A549 human lung cancer cells.
Nagappan A; Venkatarame Gowda Saralamma V; Hong GE; Lee HJ; Shin SC; Kim EH; Lee WS; Kim GS
Mol Med Rep; 2016 Oct; 14(4):3814-22. PubMed ID: 27573346
[TBL] [Abstract][Full Text] [Related]
19. Proteome analysis of multidrug resistance in vincristine-resistant human gastric cancer cell line SGC7901/VCR.
Yang YX; Xiao ZQ; Chen ZC; Zhang GY; Yi H; Zhang PF; Li JL; Zhu G
Proteomics; 2006 Mar; 6(6):2009-21. PubMed ID: 16525997
[TBL] [Abstract][Full Text] [Related]
20. Paclitaxel induced apoptosis in breast cancer cells requires cell cycle transit but not Cdc2 activity.
Henley D; Isbill M; Fernando R; Foster JS; Wimalasena J
Cancer Chemother Pharmacol; 2007 Feb; 59(2):235-49. PubMed ID: 16972069
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
